MOG and myeloid sarcoma: The establishment of highly specific assays for testing MOG-IgG has led to the development of specific diagnostic criteria of MOG-IgG associated diseases (MOGAD) and, thus, MOGAD was classified as a separate CNS inflammatory demyelinating disease distinct from AQP4+ NMOSD and MS.